JCOGの基本情報 > 研究実績 > 肝胆膵グループ

JCOGの基本情報肝胆膵グループ

更新日:2015年11月30日

  1. 論文
    1. 委員会承認の治療研究
      H Ishii, J Furuse, N Boku, et al.: JCOG Gastrointestinal Oncology Study Group. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 40(6): 573-579, 2010.
      A Takashima, C Morizane, H Ishii, et al.: Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805). Jpn J Clin Oncol. 40(12): 1189-1191, 2010.
      C Morizane, T Okusaka, J Mizusawa, et al.: Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805). Cancer Sci. 104(9): 1211-1216, 2013.
    2. グループ代表者管理の治療研究
      K Nakachi, J Furuse, T Kinoshita, et al.: A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer. Cancer Chemother Pharmacol. 66(3): 527-534, 2010.
      H Ueno, T Okusaka, J Furuse, et al.: Multicenter phase II study of gemcitabine and S-1 combination therapy (GS therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol. 41(8): 953-958, 2011.
      M Ikeda, T Ioka, Y Ito, et al.: A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 85(1): 163-169, 2013.
      M Ikeda, T Okusaka, J Furuse, et al.: A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 72(2): 463-470, 2013.
      E Suzuki, M Ikeda, T Okusaka, et al.: A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer. Cancer Chemother Pharmacol. 71(5): 1141-1146, 2013.
      T Yamaguchi, N Machida, C Morizane, et al.: Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 105(9): 1176–1181, 2014.
      A Hagihara, M Ikeda, H Ueno, et al.: A phase I study of sorafenib combined with transcatheter arterial infusion of cisplatin for advanced hepatocellular carcinoma. Cancer Sci. 105(3): 354-358, 2014.
    3. 附随研究等
      なし
    4. 総説・解説
      古瀬純司: 医学と医療の最前線「膵癌化学療法の最前線」. 日本内科学会雑誌. 99: 842-848, 2010.
      M Konishi: Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. J Hepatobiliary Pancreat Sci. 19(4): 301-305, 2012.
      J Furuse, A Kasuga, A Takasu, et al.: Role of chemotherapy in treatments for biliary tract cancer. J Hepatobiliary Pancreat Sci. 19(4): 337-341, 2012.
      J Furuse, H Ishii, T Okusaka: The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG): history and future direction. Jpn J Clin Oncol. 43(1): 2-7, 2013.
      M Ikeda, H Okuyama, H Takahashi, et al.: Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. J Hepatobiliary Pancreat Sci. 22(8): 623-627, 2015.
      池田公史、光永修一、清水怜、他: 分子標的治療薬 日本内科学会雑誌 103(1):93-101, 2014.
  2. 主な学会発表
    1. 委員会承認の治療研究
      石井浩、他: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. 第8回日本臨床腫瘍学科器学術集会. 2010年3月.
      C Morizane, et al.: Randomized phase IIlus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805) (abstract 255). Gastrointestinal Cancers Symposium. Jan 2012.
      M Ueno, et al.: Randomized phase II trial of gemcitabine plus S-1 combination therapy versus S-1 in advanced biliary tract cancer: Results of the Japan Clinical Oncology Group study (JCOG0805). 48th ASCO Annual Meeting. J Clin Oncol. 30(suppl; abstr 4031). Jun 2012.
      C Morizane, et al.: Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG 1113). J Clin Oncol. 32(suppl; abstr TPS4149). May 2014.
      C Morizane, et al: Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213). J Clin Oncol. 33(suppl; abstr TPS4143). May 2015.
      A Fukutomi, et al.: Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (JCOG1106). Poster general session. 51th ASCO Annual Meeting. J Clin Oncol. 33(suppl; abstr 4116). Jun 2015.
    2. グループ代表者管理の治療研究
      M Konishi, K Nakachi: Feasibility Study of S-1 in Resected Biliary Tract Cancer. Asia Pacific HPBA Congress 2011. (abstract P205). Sep 2011.
      小西大、仲地耕平: 胆道癌根治切除例に対するS-1による補助化学療法の安全性確認試験. 第47回日本胆道学会学術集会. 2011年9月.
      T Yamaguchi, et al.: Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of the digestive system (abstract 274). Gastrointestinal Cancers Symposium. Jan 2012.
      N Machida, et al.: Multicenter retrospective analysis of systemic chemotherapy for advanced poorly differentiated neuroendocrine carcinoma of the digestive system. 48th ASCO Annual Meeting. J Clin Oncol. 30(suppl; abstr 4046). Jun 2012.
      仲地耕平、他: 進行肝内胆管癌に対するシスプラチン肝動注化学療法の多施設共同第II相試験. 第10回日本臨床腫瘍学会学術集会. 2012年7月.
      春日章良、他: 消化器原発低分化型神経内分泌癌に対する全身化学療法の多施設共同観察研究. 2012年7月.
      小西 大、池田公史、仲地耕平: 胆道癌根治切除例に対するS-1による術後補助化学療法の多施設共同臨床試験. 第48回日本胆道学会学術集会. 2102年9月.
      T Yamaguchi, N Machida, A Kasuga, et al.: Multicenter retrospective analysis of systemic chemotherapy in poorly differentiated neuroendocrine carcinoma of digestive System. 11th Annual conference of the European Neuroendocrine Tumor Society. Mar 2013.
      清水怜、池田公史、森本学、他: 進行肝細胞癌を対象としたソラフェニブとシスプラチン肝動注の併用療法. 第50回日本肝癌研究会. 2014年6月.
      M Ikeda, S Shimizu, T Sato, et al.: Sorafenib plus intra-arterial cisplatin versus sorafenib alone in patients with advanced hepatocellular carcinoma: A randomized phaseⅡtrial. 2015 ASCO Annual Meeting (Abstract 4076). May 29- June 2, 2015.
      M Morimoto, M Ikeda, S Shimizu, et al.: A Randomized Phase 2 Trial of Sorafenib Plus Intra-Arterial Cisplatin versus Sorafenib Alone for Advanced Hepatocellular Carcinoma. 29th ILCA Annual Conference (Abstract O-022). September 4-6 2015.
    3. 附随研究等
      なし
    4. 総説・解説
      なし
トップへ戻る